Vcanbio Cell & Gene Engineering Corp

Vcanbio Cell & Gene Engineering Corp FCF Growth

The Year-over-Year Free Cash Flow Growth of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 15, 2026 is 21.21 %. In the previous year, Year-over-Year Free Cash Flow Growth was 3.55 % — a change of 497.34% (higher).

FCF Growth

21.21 %

YoY

497.34%

Last updated:

Year-over-Year Free Cash Flow Growth of Vcanbio Cell & Gene Engineering Corp is 2025 21.21 % . Year-over-Year Free Cash Flow Growth of Vcanbio Cell & Gene Engineering Corp was 2024 3.55 % . It decreases by 497.34% higher compared to the previous year.

The Vcanbio Cell & Gene Engineering Corp FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
115.29 CNY
Jan 1, 2019
5,982.66 CNY
Jan 1, 2020
28.77 CNY
Jan 1, 2021
26.59 CNY
Jan 1, 2022
-15.79 CNY
Jan 1, 2023
29.32 CNY
Jan 1, 2024
3.55 CNY
Jan 1, 2025
21.21 CNY
The Vcanbio Cell & Gene Engineering Corp FCF Growth history
YEARFCF GrowthYoY
21.21 %+497.34%
3.55 %-87.89%
29.32 %-285.62%
-15.79 %-159.41%
26.59 %-7.58%
28.77 %-99.52%
5,982.66 %+5,089.37%
115.29 %+28.24%
89.90 %-2,016.33%
-4.69 %-97.32%
-174.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vcanbio Cell & Gene Engineering Corp Stock analysis

What does Vcanbio Cell & Gene Engineering Corp do? Vcanbio Cell & Gene Engineering Corp Ltd is a biotechnology company based in Tianjin, China, operating within the healthcare sector. The company has been publicly traded since its IPO on May 4, 1993, and is listed under the ticker 600645.SS with ISIN CNE000000545. It employs 2,332 full-time staff and focuses on the development of life sciences technology. Vcanbio engages in cell culture, gene detection, and storage services, as well as the production and sale of cytokines culture solutions, cosmetics, and detection reagents. The company primarily serves domestic markets in China, with its headquarters located in Tianjin. Its website is http://www.vcanbio.com. The firm's business activities include the development and application of biotechnology solutions, though specific details on product names, acquisitions, or additional financial figures are not provided in the available information. Vcanbio operates as a public company with a presence in the Chinese biotechnology industry, emphasizing innovation in cell and gene engineering. Vcanbio Cell & Gene Engineering Corp is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock

Year-over-Year Free Cash Flow Growth of Vcanbio Cell & Gene Engineering Corp is 21.21 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Vcanbio Cell & Gene Engineering Corp historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Vcanbio Cell & Gene Engineering Corp

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Vcanbio Cell & Gene Engineering Corp